Home 主打產品 植物提取物 天然提取物 產品目錄 產品解決方案 展會 聯繫我們
沙棘果油seabuckthorn berry oil
姜黃素Turmeric Root Extract curcumin
胡椒碱piperine
阿爾法熊果甙alpha arbutin
唾液酸sialic acid
氨基丁酸γ-aminobutyric acid
紅曲米提取物Red yeast extract
紅景天提取物Rhodiola Rosea Extract
蘋果提取物Apple peel extract
虫草素cordycepin
紫錐菊提取物Echinacea extract
石榴皮提取物Pomegranate exract
橄欖葉提取物olive leaf extract
荷葉提取物lotus leaf extract
常春藤提取物Ivy leaf extract
積雪草提取物centella asiatic extract
羥基積雪草苷madecassoside
積雪草甙Asiaticoside
羥基積雪草酸madecassic acid
積雪草總甙Centella total glucosides
當歸提取物angelica extract
大蒜提取物garlic extract
淫羊藿提取物Epimedium extract icariin
問荊提取物Horsetail extract
黃芪提取物Astragalus extract
猴頭菇提取物lion's mane mushroom extract
麥苗汁粉wheat grass juice powder
絞股藍提取物gynostemma pentaphyllum extract
覆盆子提取物raspberry extract
水飛薊提取物milk thistle extract
靈芝提取物Reishi Mushroom Extract
人蔘提取物ginseng extract
大黃素Emodin

紅曲米提取物Red yeast extract 

紅曲米提取物

拉丁名: monascus purpureus

提取部位: seed

有效成分: 莫納克林

含量: Monacolin K0.1%-3%, Lovastatin0.1%-3%

規格: 5:1,10:1,20

檢測方式: TLC

CAS號碼.:75330-75-5

外觀: 紅色粉末

中國傳統藥食兩用品,用中國特有紅曲黴菌在大米中發酵培養而成,已有上千年的使用曆史。本品性狀為紅色粉末,色調純正,光熱穩定性好,純天然,安全無副作用,PH適用範圍廣。

 

產品功效:

 1.具有健脾消食,活血化瘀的作用。

2.用於降血脂,降低總膽固醇,還原酶抑制劑,直接抑制HNG-coA還原酶,阻斷膽固醇合成。

3.洛伐他汀(美降脂)能有效降低雜合於型家族性和非家族性高膽固醇血証患者的血清膽固醇含量。

【有效成分】:洛伐他汀(Lovastatin)
【提取溶劑】:乙醇
【過篩孔徑】:80目,100目
【科屬分類】曲霉科
【成分】含澱粉酶、胡蘿蔔色烯類。

【性味】甘、溫,無毒。
【性質】系釀造中的副產品,不僅烹調食物用以着色,並入藥。
【歸經】肝;脾;胃;大腸經
【產品指標】:濕度小於4%重金屬小於10ppm黴菌小於100cfu/g農藥殘留無大腸桿菌無沙門氏菌無綠膿桿菌無

產品詳詢:13657416805

參考文獻:

  1. 1.

    Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Executive summary: heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014;129:399–410.

  2. 2.

    Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003–2006. Natl Health Stat Rep. 2009:1–7.

  3. 3.

    Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab. 2008;93:S9–30.

  4. 4.

    Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, et al. The rising prevalence of diabetes and impaired glucose tolerance. The Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care. 2002;25:829–34.

  5. 5.

    Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444:875–80.

  6. 6.

    Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93.

  7. 7.

    Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia–full report. J Clin Lipidol. 2014;8:29–60.

  8. 8.

    EFSA. Scientific Opinion on the substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal blood LDL cholesterol concentrations (ID 1648, 1700) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J. 2011;9:2304. 

  9. 9.

    Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci. 2009;84:705–12.

  10. 10.

    EFSA. Scientific Opinion on the substantiation of health claims related to polyphenols in olive and protection of LDL particles from oxidative damage (ID 1333, 1638, 1639, 1696, 2865), maintenance of normal blood HDL-cholesterol concentrations (ID 1639), maintenance of normal blood pressure (ID 3781), “anti-inflammatory properties” (ID 1882), “contributes to the upper respiratory tract health” (ID 3468), “can help to maintain a normal function of gastrointestinal tract” (3779), and “contributes to body defences against external agents” (ID 3467) pursuant to Article 13(1) of Regulation (EC) No 1924/20061. EFSA J. 2011;9:2033

  11. 11.

    Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C, American Heart Association, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–8.

  12. 12.

    Rifai N, Warnick GR, McNamara JR, Belcher JD, Grinstead GF, Frantz Jr ID. Measurement of low-density-lipoprotein cholesterol in serum: a status report. Clin Chem. 1992;38:150–60.

  13. 13.

    Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003.

  14. 14.

    Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1407–8.

  15. 15.

    Yong-Guo LI, Hong L, Zheng-Tao Wang A. validated stability-indicating HPLC with photodiode array detector (PDA) method for the stress tests of Monascus purpureus-fermented rice, red yeast rice. J Pharm Biomed Anal. 2005;39:82–90. 

  16. 16.

    Navarra T, Del Turco S, Berti S, Basta G. The lectin-like oxidized low-density lipoprotein receptor-1 and its soluble form: cardiovascular implications. J Atheroscler Thromb. 2010;17:317–31.

  17. 17.

    Tsimikas S, Miller YI. Oxidative modification of lipoproteins: mechanisms, role in inflammation and potential clinical applications in cardiovascular disease. Curr Pharm Des. 2011;17:27–37.

  18. 18.

    EFSA Panel on Dietetic Products, Nutrition and Allergies. Guidance on the scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular health. EFSA J. 2011;9:2474.

  19. 19.

    Nauck M, Warnick GR, Rifai N. Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem. 2002;48:236–54.

  20. 20.

    Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol. 2011;27:635–62.

  21. 21.

    Bogsrud MP, Ose L, Langslet G, Ottestad I, Strøm EC, Hagve TA, et al. HypoCol (red yeast rice) lowers plasma cholesterol - a randomized placebo controlled study. Scand Cardiovasc J. 2010;44:197–200. doi:10.3109/14017431003624123.

  22. 22.

    Verhoeven V, Lopez Hartmann M, Remmen R, Wens J, Apers S, Van Royen P. Red yeast rice lowers cholesterol in physicians - a double blind, placebo controlled randomized trial. BMC Complement Altern Med. 2013;13:178.

  23. 23.

    Chen CH, Yang JC, Uang YS, Lin CJ. Improved dissolution rate and oral bioavailability of lovastatin in red yeast rice products. Int J Pharm. 2013;444:18–24

  24. 24.

    Venero CV, Venero JV, Wortham DC, Thompson PD. Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. Am J Cardiol. 2010;105:664–6.

  25. 25.

    Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114:1752–61.

  26. 26.

    Keaney Jr JF, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003;23:434–9.

  27. 27.

    Grattagliano I, Palmieri VO, Portincasa P, Moschetta A, Palasciano G. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem. 2008;19:491–504.

  28. 28.

    Van Guilder GP, Hoetzer GL, Greiner JJ, Stauffer BL, Desouza CA. Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. Obesity (Silver Spring). 2006;14:2127–31.

  29. 29.

    Holvoet P, Lee DH, Steffes M, Gross M, Jacobs Jr DR. Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA. 2008;299:2287–93.

  30. 30.

    Wierzbicki AS, Clarke RE, Viljoen A, Mikhailidis DP. Triglycerides: a case for treatment? Curr Opin Cardiol. 2012;27:398–404.

  31. 31.

    Ballantyne CM, Raichlen JS, Cain VA. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J Am Coll Cardiol. 2008;52:626–32.

  32. 32.

    Psaltopoulou T, Naska A, Orfanos P, Trichopoulos D, Mountokalakis T, Trichopoulou A. Olive oil, the Mediterranean diet, and arterial blood pressure: the Greek European Prospective Investigation into Cancer and Nutrition (EPIC) study. Am J Clin Nutr. 2004;80:1012–8.

  33. 33.

    Gilani AH, Khan AU, Shah AJ, Connor J, Jabeen Q. Blood pressure lowering effect of olive is mediated through calcium channel blockade. Int J Food Sci Nutr. 2005;56:613–20.

  34. 34.

    Doménech M, Roman P, Lapetra J, de la Corte FJ G, Sala-Vila A, de la Torre R. Mediterranean diet reduces 24-hour ambulatory blood pressure, blood glucose, and lipids: one-year randomized, clinical trial. Hypertension. 2014;64:69–76.

  35. 35.

    Toledo E, Hu FB, Estruch R, Buil-Cosiales P, Corella D, Salas-Salvadó J, et al. Effect of the Mediterranean diet on blood pressure in the PREDIMED trial: results from a randomized controlled trial. BMC Med. 2013;11:207. doi:10.1186/1741-7015-11-207.

  36. 36.

    Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556–64.

  37. 37.

    Matikainen N, Taskinen MR. Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes. Curr Cardiol Rep. 2012;14:721–31.

  38. 38.

    Yinhua L, Long J, Zhangrong J, Wei X, Shiwei Y, Qiu Y, et al. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for Dyslipidemia. PLoS One. 2014;9:e98611.

  39. 39.

    Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009;150:830–9.

  40. 40.

    Lapi F, Gallo E, Bernasconi S, Vietri M, Menniti-Ippolito F, Raschetti R, et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. Br J Clin Pharmacol. 2008;66:572–4.

  41. 41.

    Mueller PS. Symptomatic myopathy due to red yeast rice. Ann Intern Med. 2006;145:474–5.

  42. 42.

    Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med. 2010;170:1722–7.

  43. 43.

    Li YG, Zhang F, Wang ZT, Hu ZB. Identification and chemical profiling of monacolins in red yeast rice using high-performance liquid chromatography with photodiode array detector and mass spectrometry. J Pharm Biomed Anal. 2004;35:1101–12.

  44. 44.

    Hsin-Ping O, Wang C-CR, Lih-Shiuh L. Thermal degradation kinetics analysis of monacolin K in Monascus-fermentated products LWT. Food Sci Technol. 2009;42:292–6.


Home  |  主打產品  |  植物提取物  |  天然提取物  |  產品目錄  |  產品解決方案  |  展會  |  聯繫我們  |  網站地圖  |  手機版
  English     简体版     繁體版
網站首頁聯繫我們網站地圖